Brain cancer trial tests aggressive chemo vs. stem cell transplant

NCT ID NCT01011920

Completed Disease control Sponsor: International Extranodal Lymphoma Study Group (IELSG) Source: ClinicalTrials.gov ↗

Summary

This study tested different combinations of chemotherapy drugs, with or without a targeted antibody drug, for adults newly diagnosed with lymphoma that starts in the brain or spinal cord. After initial chemo, patients who responded well were randomly assigned to receive either radiation to the whole brain or a high-dose chemotherapy treatment supported by their own stem cells. The goal was to see which approach better controlled the cancer and kept it from coming back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

"Klinik für Hämatologie Universitätsklinikum Essen"

Essen, Germany
A.O. SS. Antonio e Biagio e Cesare Arrigo

Alessandria, Italy
AOU Pisana

Pisa, Italy
Arcispedale Santa Maria Nuova

Reggio Emilia, Italy
Azienda Ospedaliera Sanitaria Santa Maria

Terni, Italy
Azienda Ospedaliera Universitaria Senese

Siena, Italy
Azienda Sanitaria Universitaria Friuli Centrale

Udine, Italy
Casa Sollievo della Sofferenza

San Giovanni Rotondo, Italy
Friedrich Schiller Universitaet Jena

Jena, Germany
Georg-August-Universität

Göttingen, Germany
Grande Ospedale Metropolitano Niguarda

Milan, Italy
Herlev Hospital

Herlev, Denmark
Humanitas

Rozzano, Italy
IOSI - Oncology Institute of Southern Switzerland

Bellinzona, 6500, Switzerland
Istituto Nazionale Tumori, Fondazione G. Pascale

Naples, Italy
Istituto Nazionale dei Tumori Regina Elena

Roma, Italy
Istituto Tumori Giovanni Paolo II

Bari, Italy
Johannes Gutenberg Universität Mainz

Mainz, Germany
Klinikum Bremen-Mitte

Bremen, Germany
Klinikum Chemnitz

Chemnitz, Germany
Klinikum der Johann-Wolfgang- Goethe-Universität

Frankfurt am Main, Germany
Klinikum der Justus-Liebig-Universität

Giessen, Germany
Medical Oncology Unit General Hospital

Southampton, United Kingdom
Nottingham City Hospital

Nottingham, United Kingdom
Ospedale Businco

Cagliari, Italy
Ospedale Centrale di Bolzano

Bolzano, Italy
Ospedale Civile S.Spirito

Pescara, Italy
Ospedale Maggiore S. Giovanni Battista

Torino, Italy
Ospedale Umberto I

Nocera Inferiore, Italy
Ospedale degli Infermi

Rimini, Italy
Ospedale delle Croci

Ravenna, Italy
Policlinico G.B. Rossi

Verona, Italy
Queen's Hospital

Romford, United Kingdom
Rigshospitalet,

Copenhagen, Denmark
SLK-Kliniken GmbH

Heilbronn, Germany
San Raffaele H Scientific Institute

Milan, Italy
Spedali Civili

Brescia, Italy
Städtisches Klinikum

Braunschweig, Germany
Technische Universität in München

München, Germany
The Christie Hospital NHS Foundation Trust

Manchester, United Kingdom
ULSS 8 Berica - Ospedale S. Bortolo

Vicenza, Italy
Uniklinik Freiburg

Freiburg im Breisgau, Germany
University College Hospital

London, United Kingdom
University Hospital

Aarhus, Denmark
University Hospital

Aachen, Germany
University Hospital Aintree

Liverpool, United Kingdom
Università degli Studi La Sapienza

Roma, Italy
Universitätsklinikum

Cologne, Germany
Universitätsklinikum Erlangen

Erlangen, Germany
Universitätsklinikum Halle

Halle, Germany
Universitätsklinikum Ulm

Ulm, Germany
Universitätsklinikum des Saarlandes

Homburg/Saar, Germany
Universitätsklinikum und Städtisches Krankenhaus

Kiel, Germany
Universitätskrankenhaus Hamburg-Eppendorf

Hamburg, Germany

Conditions

Explore the condition pages connected to this study.

CENTRAL NERVOUS SYSTEM LYMPHOMA